*Shares rise as much as 11.5 pct to $28.06. Jan 15- Revlon Inc's controlling shareholder and billionaire, Ron Perelman, said on Friday he would seek strategic alternatives for the cosmetics maker but did not detail a specific plan. Shares of the company, the owner of Charlie perfumes and Almay cosmetics, rose as much as 11.5 percent to $28.06.
Jan 15- Billionaire Ron Perelman, the majority owner of Revlon Inc, said he would seek strategic alternatives for the cosmetics maker. New York- based Revlon, whose sales have stagnated in the last three quarters, announced a restructuring plan in September to cut costs. Avon said in December Cerberus Capital Management LP would take a 16.6 percent stake in the...
Jan 15- Billionaire Ron Perelman, the majority owner of Revlon Inc, said he would seek strategic alternatives for the cosmetics maker.
Fine jewelry is the original wearable investment and unlike the Apple Watch doesn't have to be upgraded with new technology every few years.
The Apollo appears to be in a good position to reclaim its place in pop culture, entertaining over 100,000 people a year with a $13 million budget.
Adrian Barrie Smith, who recruits housekeeping staff for the wealthy, has sued several well-known Wall Street financiers and even the comedian Jerry Seinfeld.
The SEC says Revlon has agreed to pay a $850,000 fine for misleading shareholders about details of a "going-private" transaction.
There's a battle underway in the surf-side playground of the rich and famous, reports CNBC's Robert Frank.
"I was best friends with my partners for 25 years. I mourn the loss of that friendship," Don Drapkin, the head of Casablanca Capital, said of his former business partner at MacAndrews & Forbes, financier Ron Perelman.
The chairman of the House Oversight and Government Reform Committee told CNBC that he wants to know whether political considerations drove the government’s decision to steer a potentially multibillion-dollar contract to a company in which financier Ron Perelman's investment firm has a significant stake.
Financier Ron Perelman’s entry into the smallpox antiviral medicine business has led to a congressional investigation, CNBC has learned.